Advertisement

Critical Care

, 20:17 | Cite as

Erratum to: Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome

  • Andrew D. Shaw
  • Carol R. Schermer
  • Dileep N. Lobo
  • Sibyl H. Munson
  • Victor Khangulov
  • David K Hayashida
  • John A. Kellum
Open Access
Erratum
After the publication of this article it has been brought to our attention that the data in Table 3 (Table 1 in this Erratum) and in the Additional file 3: Table S3 (Additional File 1 in this Erratum) contained mistakes as detailed below. These mistakes have been corrected in this Erratum.
Table 3

Administrative and clinical outcomes by fluid cohort

Outcome/Complication

Saline (n = 1558) % (n)

Balanced (n = 1558) % (n)

Unadjusted odds ratio (95 % CI)

Adjusted odds ratio (95 % CI)

Administrative Outcomes

Cardiac

8.66 (135)

4.43 (69)

0.488 (0.362–0.659)

0.387 (0.276–0.544)

Hemorrhage

0.71 (11)

0.51 (8)

0.726 (0.291–1.809)

0.681 (0.264–1.757)

Infectious

10.14 (158)

6.03 (94)

0.569 (0.436–0.742)

0.526 (0.396–0.699)

Gastrointestinal

5.46 (85)

5.13 (80)

0.938 (0.685–1.284)

0.881 (0.636–1.220)

Neurologic

1.16 (18)

0.83 (13)

0.72 (0.352–1.474)

0.585 (0.275–1.245)

Acute renal failure

4.36 (68)

3.34 (52)

0.757 (0.524–1.093)

0.676 (0.447–1.023)

Respiratory failure

5.46 (85)

3.47 (54)

0.622 (0.439–0.882)

0.624 (0.429–0.908)

New organ failure

9.11 (142)

7.12 (111)

0.765 (0.59–0.991)

0.707 (0.506–0.986)

Clinical Outcomes

Hospital mortality

3.27 (51)

1.03 (16)

0.307 (0.174–0.54)

0.373 (0.204–0.681)

30–day readmissions

9.5 (148)

7.64 (119)

0.788 (0.612–1.014)

0.801 (0.618–1.036)

60–day readmissions

13.54 (211)

10.91 (170)

0.782 (0.63–0.97)

0.804 (0.645–1.004)

90–day readmissions

16.56 (258)

12.58 (196)

0.725 (0.593–0.886)

0.735 (0.598–0.904)

Cardiac

Dysrhythmia

10.65 (166)

6.87 (107)

0.618 (0.48–0.797)

0.632 (0.485–0.823)

Cardiac stress

6.42 (100)

2.05 (32)

0.306 (0.204–0.458)

0.289 (0.188–0.483)

Heart failure

4.04 (63)

1.48 (23)

0.356 (0.219–0.576)

0.447 (0.268–0.747)

Hemorrhage/Hematologic

Coagulopathya

11.09 (150)

7.71 (106)

0.67 (0.516–0.87)

0.602 (0.450–0.806)

Received blood transfusion

2.92 (46)

2.27 (36)

0.777 (0.5–1.209)

0.629 (0.389–1.018)

Bleeding

20.09 (313)

19.96 (311)

0.992 (0.832–1.182)

1.134 (0.942–1.365)

Infectious

    

Pneumonia

6.03 (94)

2.12 (33)

0.337 (0.225–0.504)

0.349 (0.226–0.539)

Sepsis

10.53 (164)

5.65 (88)

0.509 (0.389–0.666)

0.534 (0.401–0.711)

Urinary tract infection

5.91 (92)

4.69 (73)

0.783 (0.571–1.074)

0.884 (0.632–1.237)

Line infection

0.77 (12)

0

Gastrointestinal

Cholecystitis

4.75 (74)

3.53 (55)

0.734 (0.514–1.048)

0.753 (0.517–1.098)

Renal

Acute Kidney Injury

5.46 (85)

4.43 (69)

0.803 (0.580–1.112)

1.052 (0.760–1.455)

Electrolyte Abnormalities

Low magnesium with replacement

4.36 (68)

2.12 (33)

0.474 (0.311–0.723)

0.565 (0.362–0.880)

High magnesium

4.43 (69)

3.4 (53)

0.760 (0.528–1.095)

0.822 (0.553–1.221)

Low potassium with replacement

14.12 (220)

7.51 (117)

0.494 (0.39–0.625)

0.510 (0.393–0.660)

High potassium

9.44 (147)

6.87 (107)

0.708 (0.546–0.918)

0.848 (0.643–1.118)

Low sodium

39.41 (614)

30.62 (477)

0.678 (0.585–0.787)

0.703 (0.602–0.821)

High sodium

7 (109)

6.03 (94)

0.854 (0.642–1.135)

0.965 (0.710–1.311)

Low calcium with replacement

1.16 (18)

0.77 (12)

0.664 (0.319–1.383)

1.125 (0.534–2.369)

Metabolic Acidosis

Lactic (pH and lactate)

0.71 (11)

0.26 (4)

0.362 (0.115–1.139)

0.397 (0.106–1.487)

Metabolic (pH and bicarbonate)

2.76 (43)

1.22 (19)

0.435 (0.252–0.75)

0.749 (0.399–1.403)

Hyperchloremic (pH and chloride)

3.47 (54)

1.22 (19)

0.344 (0.203–0.583)

0.477 (0.262–0.868)

aExcluded patients receiving warfarin

The following values have been corrected in Table 3 (Table 1 in this Erratum):
  • the entire column (far right) "Adjusted Odds Ratio (95 % CI)"

  • under Electrolyte Abnormalities, the value for "High Mg" within the column "Saline n (%)" and the values for "Unadjusted Odds Raio (95 % CI)" and "Adjusted Odds Ratio (95 % CI)"

  • under Electrolyte Abnormalities, ALL values for the row labelled "Low Ca with replacement"

The single value for SOFA CV Level 2 "Saline cohort n (%)" in Table S3 (Additional File 1 in this Erratum) has been corrected.

In addition, we noticed that the legend for Fig. 2 (Fig. 1 in this Erratum) was incorrectly given as “Administrative and clinical outcomes unadjusted and adjusted for Acute Physiology Score”. The correct legend for Fig. 2 is “Administrative and clinical outcomes unadjusted and adjusted for APS, Elixhauser comorbidities of congestive heart failure, hypertension and lymphoma, admission source, census region, and payer.” The labels above the right-hand side plots within the figure also needed corrections and have been updated in this erratum.
Fig. 2

legend, edit to: Administrative and clinical outcomes unadjusted and adjusted for APS, Elixhauser comorbidities of congestive heart failure, hypertension and lymphoma, admission source, census region, and payer

Supplementary material

13054_2016_1187_MOESM1_ESM.docx (13 kb)
Additional file 3: Table S3. SOFA Outcomes by Treatment Group. (DOCX 12 kb)

Reference

  1. 1.
    Shaw AD, Schermer CR, Lobo DN, Munson SH, Khangulov V, Hayashida DK, et al. Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome. Critical Care. 2015;19:334.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Shaw et al. 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Andrew D. Shaw
    • 1
  • Carol R. Schermer
    • 2
  • Dileep N. Lobo
    • 3
  • Sibyl H. Munson
    • 4
  • Victor Khangulov
    • 4
  • David K Hayashida
    • 4
  • John A. Kellum
    • 5
  1. 1.Department of AnesthesiologyVanderbilt University Medical CenterNashvilleUSA
  2. 2.Former Employee Baxter Healthcare CorporationDeerfieldUSA
  3. 3.Gastrointestinal Surgery, National Institute for Health Research Nottingham Digestive Diseases Biomedical Research UnitNottingham University Hospitals and University of Nottingham, Queen’s Medical CentreNottinghamUK
  4. 4.Boston Strategic Partners, Inc.BostonUSA
  5. 5.Center for Critical Care Nephrology, Department of Critical Care MedicineUniversity of PittsburghPittsburghUSA

Personalised recommendations